Literature DB >> 8163481

Identification of a uridine nucleotide-selective G-protein-linked receptor that activates phospholipase C.

E R Lazarowski1, T K Harden.   

Abstract

Incubation of C6-2B rat glioma cells with UDP or UTP resulted in a time- and concentration-dependent increase in the accumulation of inositol phosphates. In contrast, ATP, ADP, and analogs of these nucleotides known to be effective agonists at P2U-, P2X-, P2Y-, P2T-, and P2Z-purinergic receptors all had no effect on inositol phosphate levels in C6-2B cells. Pyrimidine nucleotides stimulated inositol phosphate accumulation with an order of potency of UDP > 5-BrUTP > UTP > dTDP > UDP glucose. K0.5 values for UDP, 5-BrUTP, and UTP were 2.3 +/- 0.5, 9 +/- 3, and 57 +/- 10 microM, respectively. A similar uridine nucleotide selectivity was observed for arachidonic acid release presumably occurring as a consequence of activation of phospholipase A2. Cross-desensitization and additivity experiments indicated that UDP and UTP interact with the same population of receptors. The effect of uridine nucleotides on inositol phosphate accumulation was inhibited markedly by pretreatment of cells with pertussis toxin. UDP also caused a guanine nucleotide-dependent increase in inositol lipid hydrolysis in streptolysin-O-permeabilized cells. Taken together these results describe the existence of a novel uridine nucleotide receptor that is not activated by adenine nucleotides. This receptor is pharmacologically distinct from the previously described P2U- and other P2-purinergic receptors, and likely is a member of a new class of receptors for extracellular nucleotides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163481

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Co-existence of P2Y-and PPADS-insensitive P2U-purinoceptors in endothelial cells from adrenal medulla.

Authors:  J Mateo; M T Miras-Portugal; E Castro
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Quantitation of extracellular UTP using a sensitive enzymatic assay.

Authors:  E R Lazarowski; T K Harden
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Responses of the longitudinal muscle and the muscularis mucosae of the rat duodenum to adenine and uracil nucleotides.

Authors:  C R Johnson; S J Charlton; S M Hourani
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Autocrine signaling through ATP release represents a novel mechanism for cell volume regulation.

Authors:  Y Wang; R Roman; S D Lidofsky; J G Fitz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 5.  Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system.

Authors:  E Heilbronn; B H Knoblauch; C E Müller
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

6.  Desensitization of P2U receptor in neuronal cell line. Different control by the agonists ATP and UTP, as demonstrated by single-cell Ca2+ responses.

Authors:  U Czubayko; G Reiser
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

7.  P2-Purinoceptors: Advances and therapeutic opportunities.

Authors:  Michael Williams; Kenneth A Jacobson
Journal:  Expert Opin Investig Drugs       Date:  1995-10       Impact factor: 6.206

8.  Pyrimidinoceptor-mediated activation of phospholipase C and phospholipase A2 in RAW 264.7 macrophages.

Authors:  W W Lin; Y T Lee
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

9.  UTP- and ATP-triggered transmitter release from rat sympathetic neurones via separate receptors.

Authors:  S Boehm; S Huck; P Illes
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors.

Authors:  E R Lazarowski; W C Watt; M J Stutts; H A Brown; R C Boucher; T K Harden
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.